公开(公告)号：US20240183866A1

公开(公告)日：2024-06-06

申请号：US18441255

申请日：2024-02-14

Applicant: ZORA BIOSCIENCES, OY

Inventor： Reijo LAAKSONEN

IPC: G01N33/92 ,  A61K31/164 ,  C07B59/00

CPC classification number: G01N33/92 ,  A61K31/164 ,  C07B59/001 ,  G01N2405/08 ,  G01N2458/15 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

公开(公告)号：US11874281B2

公开(公告)日：2024-01-16

申请号：US17501143

申请日：2021-10-14

Applicant: Enzo Life Sciences, Inc.

Inventor： Elazar Rabbani ,  Jannis G. Stavrianopoulos ,  Joshua Rabbani ,  Praveen Pande

IPC: G01N33/68 ,  G01N33/92 ,  C12Q1/48

CPC classification number: G01N33/6803 ,  C12Q1/485 ,  G01N33/92 ,  C12Y207/01091 ,  C12Y207/11001 ,  G01N2405/08 ,  G01N2410/00 ,  G01N2440/14 ,  G01N2440/30

Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

公开(公告)号：US20230349933A1

公开(公告)日：2023-11-02

申请号：US18140188

申请日：2023-04-27

Applicant: INSTITUT DE CARDIOLOGIE DE MONTREAL

Inventor： John D. RIOUX ,  Christine DES ROSIERS ,  Anik FOREST ,  Gabrielle BOUCHER ,  Romain FERRU-CLÉMENT

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2800/065 ,  G01N2800/52

Abstract: Disclosed are various lipid biomarkers of inflammatory bowel disease, including biomarkers for inflammatory bowel diseases including Crohn’s disease and Ulcerative colitis. Also disclosed are various biomarkers of disease location and/or disease behavior in inflammatory bowel disease. The present disclosure also provides methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, and methods of assessing efficacy of compositions for treating inflammatory bowel disease.

公开(公告)号：US20230324418A1

公开(公告)日：2023-10-12

申请号：US18021211

申请日：2021-08-13

Applicant: BAO FENG BIOTECH (BEIJING) CO., LTD

Inventor： Xianyang CHEN ,  Wangting SONG ,  Jiarui HAN ,  Teng XUE

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/08 ,  G01N2405/04 ,  G01N2405/02 ,  G01N2800/2814

Abstract: This disclosure provides a use of biomarker SM(d18:1/24:1(15Z)) in the preparation of a reagent or kit for diagnosing cognitive impairment. This disclosure also provides a method for diagnosing and treating cognitive impairment by detecting the content of biomarkers SM(d18:1/24:1(15Z)) and TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z)), PC(P-16:0/22:4(7Z,10Z,13Z,16Z) or PC(P-18:0/18:4(6Z,9Z,12Z,15Z)) to determine whether the patient has cognitive impairment.

公开(公告)号：US20170030935A9

公开(公告)日：2017-02-02

申请号：US14761587

申请日：2014-01-23

Applicant: The Regents of the University of California

Inventor： Katherine B. LOUIE ,  Benjamin P. BOWEN ,  Trent R. NORTHEN

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N33/574 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2458/15 ,  G01N2560/00 ,  G01N2800/7028

Abstract: Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject.

Abstract translation: 本文公开了用于鉴定受试者中的一种或多种患病细胞的方法，用于癌症诊断的方法，用于确定受试者中癌症进展的方法和用于评估受试者的健康状况的方法。

公开(公告)号：US20160310454A1

公开(公告)日：2016-10-27

申请号：US15105532

申请日：2014-12-17

Applicant: Jeanine D'ARMIENTO ,  Piotr SKLEPKIEWICZ ,  Vincent LEMAITRE

Inventor： Jeanine D'Armiento ,  Vincent Lemaitre

IPC: A61K31/18 ,  G01N33/92 ,  A61K31/195 ,  C12N15/113

CPC classification number: A61K31/18 ,  A61K31/195 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/3233 ,  C12N2320/30 ,  G01N33/92 ,  G01N2405/00 ,  G01N2405/08 ,  G01N2800/122 ,  G01N2800/52

Abstract: The present invention provides methods and compositions for treating a subject afflicted with chronic obstructive pulmonary disease (COPD) which comprise a i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist. The present invention also provides methods and compositions for use in prophylactically treating a subject for chronic obstructive pulmonary disease (COPD) which comprise i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist.

Abstract translation: 本发明提供用于治疗患有慢性阻塞性肺疾病（COPD）的受试者的方法和组合物，其包含ai）肝X受体（LXR）激动剂，ii）miR-33拮抗剂，或iii）TLR4 / Myd88途径拮抗剂 。 本发明还提供了用于预防性治疗慢性阻塞性肺疾病（COPD）的受试者的方法和组合物，其包括i）肝X受体（LXR）激动剂，ii）miR-33拮抗剂，或iii）TLR4 / Myd88途径拮抗剂。

公开(公告)号：US20160305931A1

公开(公告)日：2016-10-20

申请号：US14795163

申请日：2015-07-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Byung Hwa JUNG ,  Jong Min CHOI ,  Hong Seog SEO

IPC: G01N33/49

CPC classification number: G01N33/492 ,  G01N33/6893 ,  G01N2405/02 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2570/00 ,  G01N2800/324

Abstract: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Abstract translation: 本公开提供了使用一种或多种选自色氨酸，高丝氨酸，脂肪酸（16:1），脂肪酸（18：0），脂肪酸（18：1），脂肪酸 （18:2），脂肪酸（22:6），磷脂酰胆碱（PC）（34:2），PC（34:3），溶血磷脂酰胆碱（溶血卵磷脂）（16：0），溶血卵磷脂（18：0） 20：3），lysoPC（20：4），溶血卵磷脂（22：6），单甘油酯（18：1：0：0/0：0）和鞘磷脂（d18：2/16：0） 通过体内水平分析简单准确地诊断急性冠状动脉综合征以及发病前的症状。

公开(公告)号：US20160266152A1

公开(公告)日：2016-09-15

申请号：US15159650

申请日：2016-05-19

Applicant: ZORA BIOSCIENCES, OY

Inventor： Reijo Laaksonen

IPC: G01N33/92 ,  A61K31/164

CPC classification number: G01N33/92 ,  A61K31/164 ,  C07B59/001 ,  G01N2405/08 ,  G01N2458/15 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

公开(公告)号：US20150031572A1

公开(公告)日：2015-01-29

申请号：US14377603

申请日：2013-02-15

Applicant: BASF SE

Inventor： Tilmann B. Walk ,  Bennard van Ravenzwaay ,  Werner Mellert ,  Eric Fabian ,  Volker Strauss ,  Hennicke Kamp ,  Jan C. Wiemer ,  Ralf Looser ,  Michael Manfred Herold ,  Alexandre Prokoudine

IPC: G01N33/50 ,  G01N33/68 ,  G01N33/94 ,  G01N33/92

CPC classification number: G01N33/5014 ,  G01N33/5038 ,  G01N33/5088 ,  G01N33/6848 ,  G01N33/92 ,  G01N33/942 ,  G01N2405/02 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2570/00 ,  Y10T436/145555

Abstract: The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

Abstract translation: 本发明涉及用于化学化合物危险分层的神经元毒性和毒理学评估的诊断领域。 具体地说，涉及诊断神经元毒性的方法。 它还涉及一种用于确定化合物是否能够在受试者中诱导这种神经元毒性的方法以及鉴定用于治疗神经元毒性的药物的方法。 此外，本发明涉及用于诊断神经元毒性的装置和试剂盒。

公开(公告)号：US20150005471A1

公开(公告)日：2015-01-01

申请号：US14296756

申请日：2014-06-05

Applicant: ENZO BIOCHEM, INC.

Inventor： ELAZAR RABBANI ,  JOSHUA RABBANI ,  PRAVEEN PANDE ,  JANNIS G. STAVRIANOPOULOS

IPC: C12Q1/48

CPC classification number: G01N33/6803 ,  C12Q1/485 ,  C12Y207/01091 ,  C12Y207/11001 ,  G01N33/92 ,  G01N2405/08 ,  G01N2410/00 ,  G01N2440/14 ,  G01N2440/30

Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

Abstract translation: 提供的方法和组合物可用于分离，分离，检测和定量已经由尚未被这样修饰的其它化合物化学，酶促或催化改性的化合物。 这些修饰可以采取由感兴趣的化合物获得，丢失或保留的官能团的形式。